Isis Pharmaceuticals Reports ISIS 301012 Significantly Reduces All Atherogenic Lipids When Dosed as a Single Agent and When Coadministered With Statins
ISIS 301012 Coadministered with Statins
More about Phase 2 Trials for ISIS 301012